Emergent BioSolutions Inc. EBS
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -260.70M | -176.80M | -8.60M | 52.60M | 75.90M |
| Total Depreciation and Amortization | 90.50M | 96.90M | 96.40M | 98.30M | 101.50M |
| Total Amortization of Deferred Charges | 7.60M | 8.50M | 9.30M | 9.80M | 9.40M |
| Total Other Non-Cash Items | 224.90M | 245.00M | 6.40M | 32.30M | 15.90M |
| Change in Net Operating Assets | 137.80M | -75.90M | 44.50M | -22.40M | -189.70M |
| Cash from Operations | 200.10M | 97.70M | 148.00M | 170.60M | 13.00M |
| Capital Expenditure | -11.70M | -11.80M | -12.60M | -13.80M | -11.60M |
| Sale of Property, Plant, and Equipment | 5.60M | 200.00K | 100.00K | 38.20M | 38.50M |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | 0.00 |
| Other Investing Activities | -47.90M | -50.40M | 20.00M | 45.00M | 75.00M |
| Cash from Investing | -54.00M | -62.00M | 7.50M | 69.40M | 101.90M |
| Total Debt Issued | 145.50M | 145.50M | -- | -- | 0.00 |
| Total Debt Repaid | -324.10M | -262.50M | -112.50M | -112.50M | -6.90M |
| Issuance of Common Stock | 2.70M | 2.80M | 2.50M | 2.20M | 1.80M |
| Repurchase of Common Stock | -31.00M | -39.90M | -37.60M | -26.30M | -17.10M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -11.50M | -11.50M | -- | -- | 0.00 |
| Cash from Financing | -218.40M | -165.60M | -147.60M | -136.60M | -22.20M |
| Foreign Exchange rate Adjustments | 0.00 | -200.00K | 800.00K | 100.00K | 100.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -72.30M | -130.10M | 8.70M | 103.50M | 92.80M |